This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Conjugated estrogen
Description: Premarin is an estrogen-only therapy. Taken alone, it is appropriate for women who are experiencing menopausal symptoms and do not have a uterus.
Deal Structure: Premarin was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
In June 2012, Takeda and Pfizer announced that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products that it previously procured from Wyeth and currently distributes in Japan under an exclusive distribution agreement with Pfizer, and that Pfizer, the manufacturer of the products, will begin selling them thereafter. This drug is included in the 13 products Takeda will no longer distribute.
Pink Sheet Premarin price increase
Pink Sheet Wyeth Modifies Premarin Warnings Slightly
Pink Sheet Wyeth Premarin approval
Pink Sheet Premarin reformulation approved
Additional information available to subscribers only: